Cargando…
The First WHO International Standard for Harmonizing the Biological Activity of Bevacizumab
Several Bevacizumab products are approved for clinical use, with many others in late-stage clinical development worldwide. To aid the harmonization of potency assessment across different Bevacizumab products, the first World Health Organization (WHO) International Standard (IS) for Bevacizumab has b...
Autores principales: | Jia, Haiyan, Harikumar, Parvathy, Atkinson, Eleanor, Rigsby, Peter, Wadhwa, Meenu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615914/ https://www.ncbi.nlm.nih.gov/pubmed/34827607 http://dx.doi.org/10.3390/biom11111610 |
Ejemplares similares
-
The First WHO International Standard for Adalimumab: Dual Role in Bioactivity and Therapeutic Drug Monitoring
por: Wadhwa, Meenu, et al.
Publicado: (2021) -
The first World Health Organization International Standard for infliximab products: A step towards maintaining harmonized biological activity
por: Metcalfe, Clive, et al.
Publicado: (2018) -
Establishment of the first international standard for PEGylated granulocyte colony stimulating factor (PEG-G-CSF): Report of an international collaborative study
por: Wadhwa, Meenu, et al.
Publicado: (2015) -
Harmonization of Zika neutralization assays by using the WHO International Standard for anti-Zika virus antibody
por: Mattiuzzo, Giada, et al.
Publicado: (2019) -
Establishment of the first WHO International Standard for antiserum to Respiratory Syncytial Virus: Report of an international collaborative study
por: McDonald, Jacqueline U., et al.
Publicado: (2018)